Search
CYNK-101
go.drugbank.com/drugs/DB18637InvestigationalCYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Pafuramidine
go.drugbank.com/drugs/DB06532InvestigationalPafuramidine, a prodrug of furamidine, currently has orphan status for Pneumocystis jiroveci pneumonia.
RPI-78M
go.drugbank.com/drugs/DB05740ExperimentalRPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
AT-7519
go.drugbank.com/drugs/DB08142InvestigationalAT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.
Synonyms: 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamideCefilavancin
go.drugbank.com/drugs/DB05735InvestigationalCefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.
ZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalAs of August, 2020 the candidate is in Phase II clinical trials[A219758]. … The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758].